TABLE 4.
Dry skin and skin irritation related to topical acne treatment
| # | AUTHORS/JOURNAL | TITLE | DRY SKIN AND SKIN IRRITATION | EVIDENCE LEVEL |
|---|---|---|---|---|
| 1 | Drealos ZD, Callender V, Young C, Sunil SD. Cutis. 2008;82:281-284. | The effect of vehicle formulation on acne medication tolerability. | Dryness and peeling and irritation occur in topical treatment with BPO and retinoids. | 2 |
| 2 | Thiboutot DM, Weiss J, Bucko A, et al. J Am Acad Dermatol. 2007;57:791-799. | Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. | AEs reported were dry skin, erythema and desquamation. Similar adverse event frequency and tolerability profile for combination gel vs. adapalene monotherapy. | 2 |
| 3 | Andres P, Pernin C, Poncet M. Cutis. 2008;81:278-284. | Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants. | Adapalene 0.1%-BPO 5% caused more irritation than BPO 5% or 10% monotherapy. | 1 |
| 4 | Troielli PA, Asis B, Bermejo A, et al. Skinmed. 2010;8:17-22. | Community study of fixed-combination adapalene 0.1% and benzoyl peroxide 2.5% in acne. | Erythema, scaling, itching, burning, and stinging were all reported. | 2 |
| 5 | Gollnick HP, Draelos Z, Glenn MJ, et al. Br J Dermatol. 2009;161:1180-1189. | Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1,670 patients. | AEs dry skin, erythema and desquamation. Adapalene-BPO showed significantly greater efficacy than monotherapies. | 2 |
| 6 | Gold LS, Tan J, Cruz-Santana A, et al. Cutis. 2009;84:110-116. | A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. | AEs reported were dry skin, erythema, and desquamation.Comparable safety of adapalene-BPO to monotherapies and gel vehicle. | 2 |
| 7 | Poulin Y, Sanchez NP, Bucko A, et al. Br J Dermatol. 2011 Apr 1; [Epub ahead of print]. | A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among severe acne vulgaris patients: results of a randomized controlled trial | AEs reported were dry skin, erythema, and desquamation for adapalene-BPO. | 2 |
| 8 | Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alio AB. Cutis. 2009;84:223-229. | Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. | RCT: Combination therapies adapalene-BPO and BPO/clin: application site dryness, desquamation, burning, erythema, and pruritus occurred and were less common in subjects using clindamycin. | 2 |
| 9 | Loesche C, Pernin C, Poncet M. Eur J Dermatol. 2008;18:524-526. | Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. | Study analyzed tolerability only; no significant difference in irritation indices for adapalene-BPO vsmonotherapies. With erythema and desquamation as the most frequent AEs | 2 |